Health
Stopping GLP-1 drugs cuts heart benefits by 22%
Study finds stopping GLP-1 medications for diabetes and weight loss reverses cardiovascular protection, increasing event risks significantly.
A new study published in BMJ Medicine reveals that the cardiovascular benefits associated with certain drugs used to treat diabetes and promote weight loss diminish after patients stop taking them. This decline occurs even if the individual maintained a long-term regimen prior to discontinuation.
Study scope and participant data
The research analyzed data from 333,687 individuals diagnosed with type 2 diabetes. Among this cohort, 132,551 participants began using medications from the GLP-1 class. Researchers tracked these subjects for a period extending up to three years to assess health outcomes relative to their medication status.
Risk changes upon treatment cessation
Continuous use of GLP-1 drugs was linked to an 18% reduction in the risk of heart attack, stroke, or death compared to users of another class of diabetes medications. Conversely, stopping the medication for one year correlated with a 14% increase in the risk of these adverse events. After two years without the drug, the risk rose by 22% compared to those who continued their therapy. Resuming the medication was associated with a partial return of the protective heart benefits.
Mechanisms beyond weight loss
The findings suggest that the therapeutic impact may extend beyond weight reduction alone. The use of these drugs is connected to improvements in specific indicators related to heart health, including blood sugar levels, blood pressure, and blood lipids. However, the study identified correlations between medication usage patterns and cardiac risks rather than proving that stopping the drug is the direct cause of increased danger.
Limitations and medical advice
Results are restricted to people with type 2 diabetes, meaning the percentages cannot be directly generalized to individuals who use these medications solely for weight loss purposes. Patients considering halting their treatment are advised to consult their physician to establish a plan suited to their condition and to monitor health indicators following discontinuation.
